EVM
INFI

Eaton Vance Management’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Eaton Vance Management’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,000
Closed -$2K – 2835
2021
Q4 		$2K Buy
+1,000
New +$2.51K ﹤0.01% 2751

Other funds holding INFI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Eaton Vance Management's INFI Position: Q1 2022 in Review

Eaton Vance Management sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2022, closing a stake of 1,000 shares — an estimated $2K sold.

Eaton Vance Management first reported a position in INFI in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 93 funds tracked by Wall St. Rank hold INFI as of Q1 2022.

  • Eaton Vance Management reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 1,000 Infinity Pharmaceuticals, Inc. shares in Q1 2022, an estimated $2K.
  • Eaton Vance Management first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2021 and held it in 1 quarter.
  • Eaton Vance Management's Infinity Pharmaceuticals, Inc. position peaked at $2K in Q4 2021.
  • 93 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.